Adult Immune Thrombocytopenia Purpura

Adult Immune Thrombocytopenia Purpura

Episodes

Specialty:

All

Year:

All

EP. 1: Adult ITP: Causes and Pathophysiology

January 27th 2020

EP. 2: Risks of Bleeding and Thrombosis in Adult ITP

January 27th 2020

EP. 3: Tests to Aid in the Diagnosis of Adult ITP

January 27th 2020

EP. 4: Adult ITP: When Is It Appropriate to Initiate Therapy?

January 27th 2020

EP. 5: Frontline Corticosteroid Strategies in Adult ITP

January 27th 2020

EP. 6: 2019 ASH Guideline Update on Treating Relapsed/Refractory ITP

January 27th 2020

EP. 7: Targeting Syk in Adult Immune Thrombocytopenic Purpura

January 27th 2020

EP. 8: Syk Inhibition in Adult ITP: The FIT1 and FIT2 Trials

January 27th 2020

EP. 9: Adult Immune Thrombocytopenic Purpura: TPO Receptor Agonists

January 27th 2020

EP. 10: Rituximab or Platelet Transfusion in ITP

January 27th 2020

EP. 11: Later-Line Treatment Options in Adult ITP

January 27th 2020

EP. 12: Adult ITP: Promising Therapeutic Agents in Development

January 27th 2020

EP. 13: Use of Splenectomy in Adult Immune Thrombocytopenic Purpura

January 27th 2020

Trending on OncLive

CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care

Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications

FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS

Olaparib Maintenance Yields Promising Long-Term OS Outcomes in Asian Patients With Platinum-Sensitive, Relapsed Ovarian Cancer

Five Under 5: Top Oncology Videos for the Week of 9/13